AVANT's CEO to Present at the BIO CEO & Investor Conference.NEEDHAM, Mass. -- AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) announced today that Dr. Una S. Ryan, AVANT's President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , will be presenting on Monday, February 12th at 2:45 p.m. Eastern Time at the Biotechnology Industry Organization's BIO CEO & Investor Conference in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. . This presentation will be webcast live, with replays available for approximately 4 weeks, through the investor information section of AVANT's website (www.avantimmune.com) or through the conference website run by BIO (www.bio.org). Earlier on Monday, February 12th at 9:45 a.m. ET, Dr. Ryan will participate on a panel discussion on pandemic pandemic /pan·dem·ic/ (pan-dem´ik) 1. a widespread epidemic of a disease. 2. widely epidemic. pan·dem·ic adj. Epidemic over a wide geographic area. n. flu entitled "Pandemic Panic - The Current State of Vaccine Research" moderated by Navdeep Jaikaira, Ph.D., Senior Analyst and Managing Director at Rodman & Renshaw, LLC (Logical Link Control) See "LANs" under data link protocol. LLC - Logical Link Control . About AVANT Immunotherapeutics, Inc. AVANT Immunotherapeutics, Inc. discovers and develops innovative vaccines and therapeutics that harness the human immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. to prevent and treat disease. AVANT has three products on the market and five of AVANT's products are in clinical development. AVANT's pipeline includes products for biodefense, travelers' vaccines, global health, and pandemic flu needs based on AVANT's oral, rapid-protecting, single-dose and temperature stable vaccine technology. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion